ScripUltragenyx Says CRL Discussions ‘Productive’ Ultragenyx received a complete response letter for UX111, a gene therapy for patients with the rare terminal neurodegenerative disease Sanfilippo syndrome
ScripNot quite two years after raising $175m in series C cash , inhaled respiratory therapy-focused Avalyn Pharma revealed on July 22 that it has raised a $100m series D round that CEO Lyn Baranowski said
ScripRoivant has promised investors it will spend some of its impressive cash stockpile on buying new assets. But midway into the year, no deals have been signed. CEO Matt Gline, in an interview at the com
ScripRoivant’s confidence in Immunovant’s neonatal fragment crystallizable receptor (FcRn) inhibitor IMVT-1402 has only grown, Roivant CEO Matt Gline said, since the company and its subsidiary announced ea